Last week, readers were most interested in a story about Lumos Dx's completion of a clinical trial for its FebriDx test and the submission of it for CLIA waiver.

The company's laboratory-developed test (LDT) for neurofilament light chain (NfL) also gained New York state approval as part of the permitting process.

The program offers lower-cost, refurbished testing instruments as well as customer education, inventory management, and enhanced service agreements.

Financial and other terms of the deal were not disclosed.

The all-virtual program is currently looking for a second cohort of novel diagnostics technologies, with a Sept. 30 deadline for new applications.

According to a company executive, the transactions will provide QuidelOrtho with greater financial flexibility while funding its continued growth.

NEW YORK — The Scottish government has earmarked £800,000 ($1.1 million) to support the introduction of a Genedrive test to help prevent antibiotic-induced deafness in newborns within the country, ...

Reviewers winnowed an initial 27 assays to a group of nine that were evaluated using NCI sample sets, ultimately choosing ClearNote's Avantect and Guardant's Shield.